Search Results - "Bratengeier, C."

Mechanical loading intensities affect the release of extracellular vesicles from mouse bone marrow‐derived hematopoietic progenitor cells and change their osteoclast‐modulating effect by Bratengeier, C., Johansson, L., Liszka, A., Bakker, A. D., Hallbeck, M., Fahlgren, A.

“…Low‐intensity loading maintains or increases bone mass, whereas lack of mechanical loading and high‐intensity loading decreases bone mass, possibly via the…”
Get full text

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide by Polyzos, S. A., Anastasilakis, A. D., Bratengeier, C., Woloszczuk, W., Papatheodorou, A., Terpos, E.

“…Summary Sclerostin is expressed by osteocytes and inhibits bone formation by osteoblasts. In this study, serum sclerostin was positively correlated with either…”
Get full text

Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis by TERPOS, E, FRAGIADAKI, K, KONSTA, M, BRATENGEIER, C, PAPATHEODOROU, A, SFIKAKIS, P. P

“…A critical role of interleukin-6 (IL-6) in bone homeostasis has been suggested in experimental studies. We examined whether inhibition of IL-6 receptor in…”
Get full text

High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density by Voskaridou, E, Christoulas, D, Plata, E, Bratengeier, C, Anastasilakis, A D, Komninaka, V, Kaliontzi, D, Gkotzamanidou, M, Polyzos, S A, Dimopoulou, M, Terpos, E

“…Osteoporosis is a severe complication of thalassemia. Sclerostin is a Wnt signaling inhibitor, which is produced by osteocytes and inhibits osteoblast…”
Get more information

Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone by Piemonte, S., Romagnoli, E., Bratengeier, C., Woloszczuk, W., Tancredi, A., Pepe, J., Cipriani, C., Minisola, S.

“…Objective: This study was carried out in order to evaluate the effect of 18-month treatment with PTH (1–34) or PTH (1–84) on serum sclerostin levels in humans…”
Get full text

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women — The six-month effect of risedronate and teriparatide by Polyzos, S.A, Anastasilakis, A.D, Bratengeier, C, Woloszczuk, W, Papatheodorou, A, Terpos, E

Get full text

Dickkopf-1 and sclerostin in different phases of multiple myeloma; The effect of lenalidomide and dexamethasone treatment with or without bortezomib by Terpos, E, Christoulas, D, Gkotzamanidou, M, Bratengeier, C, Gavriatopoulou, M, Woloszczuk, W, Kastritis, E, Dimopoulos, M.A

Get full text

Serum sclerostin levels decline in postmenopausal women with osteoporosis following treatment with intermittent PTH by Piemonte, S, Romagnoli, E, Pepe, J, Del Fiacco, R, Cipriani, C, Bratengeier, C, Woloszczuk, W, Tancredi, A, Minisola, S

Get full text

High Serum Sclerostin Correlates with Advanced Stage, Increased Bone Resorption, Reduced Osteoblast Function, and Poor Survival in Newly-Diagnosed Patients with Multiple Myeloma by Terpos, Evangelos, Christoulas, Dimitrios, Katodritou, Eirini, Bratengeier, Cornelia, Lindner, Brigitte, Harmelin, Silvia, Hawa, Gerhard, Boutsikas, Georgios, Migkou, Magdalini, Gavriatopoulou, Maria, Michalis, Eurydiki, Pouli, Anastasia, Kastritis, Efstathios, Zervas, Konstantinos, Dimopoulos, Meletios A.

“…Abstract 425 Multiple myeloma (MM) is characterized by the presence of lytic bone disease due to increased osteoclast activity which is accompanied by reduced…”
Get full text